Haemonetics Corporation (Haemonetics) is a healthcare company. The Company provides various products to customers involved in the processing, handling and analysis of blood. The Company's segments include Japan, EMEA, North America Plasma and All Other. Haemonetics provides plasma collection systems and software, which enable plasma fractionators to make pharmaceuticals. The Company enables plasma collection customers to source from it a range of products necessary for plasma collection and storage, including PCS brand plasma collection equipment and disposables, plasma collection containers and intravenous solutions, such as saline. Haemonetics offers automated blood component and manual whole blood collection systems to blood collection centers to collect blood products. The Company offers a range of blood management solutions. The Company has a suite of integrated software solutions, which include solutions for blood drive planning and blood collection.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Medical Equipment, Supplies & Distribution
- Sub-Industry: Health Care Supplies
- Symbol: NYSE:HAE
- CUSIP: 40502410
- Web: www.haemonetics.com
Capitalization:- Market Cap: $2.26 billion
- Outstanding Shares: 52,606,000
Average Prices:- 50 Day Moving Avg: $42.17
- 200 Day Moving Avg: $40.91
- 52 Week Range: $32.76 - $43.77
P/E:- Trailing P/E Ratio: 558.83
- Foreward P/E Ratio: 23.51
- P/E Growth: 3.15
Sales & Book Value:- Annual Revenue: $887.11 million
- Price / Sales: 2.55
- Book Value: $14.71 per share
- Price / Book: 2.93
Profitability:- EBIDTA: $164.54 million
- Net Margins: 0.48%
- Return on Equity: 11.07%
- Return on Assets: 6.54%
Debt:- Debt-to-Equity Ratio: 0.31%
- Current Ratio: 2.57%
- Quick Ratio: 1.72%
Misc:- Average Volume: 321,498 shs.
- Beta: 0.89
- Short Ratio: 9.35
Frequently Asked Questions for Haemonetics Corporation (NYSE:HAE)
What is Haemonetics Corporation's stock symbol?
Haemonetics Corporation trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."
How were Haemonetics Corporation's earnings last quarter?
Haemonetics Corporation (NYSE:HAE) issued its earnings results on Monday, August, 7th. The company reported $0.33 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.02. The firm had revenue of $211 million for the quarter, compared to analysts' expectations of $211.29 million. Haemonetics Corporation had a net margin of 0.48% and a return on equity of 11.07%. The business's revenue was up .5% on a year-over-year basis. During the same quarter last year, the business earned $0.25 earnings per share. View Haemonetics Corporation's Earnings History.
When will Haemonetics Corporation make its next earnings announcement?
Where is Haemonetics Corporation's stock going? Where will Haemonetics Corporation's stock price be in 2017?
6 brokerages have issued 12-month price targets for Haemonetics Corporation's shares. Their predictions range from $24.00 to $50.00. On average, they expect Haemonetics Corporation's stock price to reach $40.80 in the next year. View Analyst Ratings for Haemonetics Corporation.
Who are some of Haemonetics Corporation's key competitors?
Some companies that are related to Haemonetics Corporation include VWR Corporation (VWR), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), Neogen Corporation (NEOG), NuVasive (NUVA), Nevro Corp (NVRO), Halyard Health (HYH), Inogen (INGN), CONMED Corporation (CNMD), MiMedx Group (MDXG), OraSure Technologies (OSUR), Asante Solutions (PUMP), Cardiovascular Systems (CSII), K2M Group Holdings (KTWO), Orthofix International N.V. (OFIX), Intersect ENT (XENT) and AtriCure (ATRC).
Who are Haemonetics Corporation's key executives?
Haemonetics Corporation's management team includes the folowing people:
- Christopher Simon, President, Chief Executive Officer, Director
- William P. Burke, Chief Financial Officer, Executive Vice President
- Michelle Basil, Executive Vice President, General Counsel
- Neil Ryding, Executive Vice President, Global Operations
- Richard J. Meelia, Non-Executive Independent Chairman of the Board
- Catherine M. Burzik, Independent Director
- Charles J. Dockendorff, Independent Director
- Susan Bartlett Foote, Independent Director
- Ronald G. Gelbman, Independent Director
Who owns Haemonetics Corporation stock?
Haemonetics Corporation's stock is owned by many different of institutional and retail investors. Top institutional investors include BlackRock Inc. (11.92%), Vanguard Group Inc. (9.03%), Wells Fargo & Company MN (5.31%), Victory Capital Management Inc. (3.87%), Neuberger Berman Group LLC (3.55%) and HealthCor Management L.P. (3.53%). Company insiders that own Haemonetics Corporation stock include Byron Selman, Christopher J Lindop, Christopher Simon, Ronald G Gelbman, Ronald Merriman, Sandra Jesse and Susan M Hanlon. View Institutional Ownership Trends for Haemonetics Corporation.
Who sold Haemonetics Corporation stock? Who is selling Haemonetics Corporation stock?
Haemonetics Corporation's stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Parametric Portfolio Associates LLC, Neuberger Berman Group LLC, Thrivent Financial For Lutherans, American Capital Management Inc., BTIM Corp., Goldman Sachs Group Inc. and Heartland Advisors Inc.. Company insiders that have sold Haemonetics Corporation stock in the last year include Ronald G Gelbman and Ronald Merriman. View Insider Buying and Selling for Haemonetics Corporation.
Who bought Haemonetics Corporation stock? Who is buying Haemonetics Corporation stock?
Haemonetics Corporation's stock was purchased by a variety of institutional investors in the last quarter, including HealthCor Management L.P., Wells Fargo & Company MN, Anchor Capital Advisors LLC, Arrowstreet Capital Limited Partnership, Ameriprise Financial Inc., Renaissance Technologies LLC, Balyasny Asset Management LLC and Van Berkom & Associates Inc.. View Insider Buying and Selling for Haemonetics Corporation.
How do I buy Haemonetics Corporation stock?
Shares of Haemonetics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Haemonetics Corporation's stock price today?
One share of Haemonetics Corporation stock can currently be purchased for approximately $43.03.
MarketBeat Community Rating for Haemonetics Corporation (NYSE HAE)MarketBeat's community ratings are surveys of what our community members think about Haemonetics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Haemonetics Corporation (NYSE:HAE) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Sell Rating, 2 Hold Ratings, 3 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.33) |
| Consensus Price Target: | $40.80 (5.18% downside) |
Analysts' Ratings History for Haemonetics Corporation (NYSE:HAE)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 8/8/2017 | Barrington Research | Upgrade | Market Perform -> Outperform | $48.00 | High |  |
| 7/27/2017 | Jefferies Group LLC | Reiterated Rating | Buy | $48.00 | High | |
| 7/13/2017 | JMP Securities | Upgrade | Market Perform -> Outperform | $50.00 | High | |
| 11/7/2016 | BTIG Research | Reiterated Rating | Neutral | | N/A | |
| 11/7/2016 | Benchmark Co. | Boost Price Target | Hold | $32.00 -> $34.00 | N/A | |
| 10/14/2016 | Off Wall Street | Initiated Coverage | Sell | $24.00 | N/A | |
| 9/20/2016 | CJS Securities | Downgrade | Market Outperform -> Market Perform | $35.00 | N/A | |
| 8/15/2016 | Sidoti | Downgrade | Buy -> Neutral | $39.00 | N/A | |
| 5/16/2016 | Goldman Sachs Group, Inc. (The) | Upgrade | Sell -> Neutral | $29.00 | N/A | |
| 5/12/2016 | Morgan Stanley | Reiterated Rating | Hold | | N/A | |
| 2/2/2016 | William Blair | Reiterated Rating | Market Perform | | N/A | |
| 11/23/2015 | Raymond James Financial, Inc. | Downgrade | Market Perform -> Underperform | | N/A | |
(Data available from 9/23/2015 forward)
Earnings History for Haemonetics Corporation (NYSE:HAE)Earnings History by Quarter for Haemonetics Corporation (NYSE HAE)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/6/2017 | | | | | | | | |
| 8/7/2017 | Q1 2018 | $0.31 | $0.33 | $211.29 million | $211.00 million | View | Listen | |
| 5/8/2017 | Q4 2017 | $0.37 | $0.39 | $215.06 million | $228.10 million | View | Listen | |
| 2/6/2017 | Q317 | $0.40 | $0.43 | $220.00 million | $227.80 million | View | Listen | |
| 11/7/2016 | Q217 | $0.35 | $0.46 | $210.72 million | $220.30 million | View | Listen | |
| 8/1/2016 | Q117 | $0.28 | $0.25 | $205.41 million | $210.00 million | View | Listen | |
| 5/2/2016 | Q416 | $0.46 | $0.37 | $245.08 million | $243.20 million | View | Listen | |
| 2/1/2016 | Q316 | $0.46 | $0.48 | $237.37 million | $233.40 million | View | Listen | |
| 11/4/2015 | Q216 | $0.40 | $0.44 | $226.50 million | $219.70 million | View | Listen | |
| 7/27/2015 | Q116 | $0.33 | $0.35 | $215.62 million | $213.40 million | View | Listen | |
| 4/27/2015 | Q415 | $0.51 | $0.47 | $239.20 million | $226.50 million | View | Listen | |
| 1/29/2015 | Q315 | $0.51 | $0.53 | $235.45 million | $231.80 million | View | Listen | |
| 11/3/2014 | Q215 | $0.45 | $0.47 | $229.90 million | $227.60 million | View | Listen | |
| 7/30/2014 | Q115 | $0.35 | $0.38 | $215.85 million | $224.49 million | View | Listen | |
| 4/28/2014 | Q414 | $0.58 | $0.46 | $244.87 million | $241.00 million | View | Listen | |
| 1/27/2014 | Q314 | $0.61 | $0.61 | $243.71 million | $242.10 million | View | Listen | |
| 10/28/2013 | Q214 | $0.57 | $0.66 | $239.51 million | $235.80 million | View | Listen | |
| 7/29/2013 | Q1 2014 | $0.47 | $0.46 | $232.98 million | $219.50 million | View | Listen | |
| 5/1/2013 | Q4 2013 | $0.46 | $0.48 | $249.33 million | $249.90 million | View | Listen | |
| 1/30/2013 | Q3 2013 | $0.47 | $0.50 | $251.93 million | $247.40 million | View | Listen | |
| 10/29/2012 | Q213 | $0.77 | $0.90 | $223.47 million | $218.18 million | View | N/A | |
| 8/1/2012 | | $0.71 | $0.55 | | | View | N/A | |
| 4/30/2012 | | $0.83 | $0.80 | | | View | N/A | |
| 1/30/2012 | | $0.80 | $0.86 | | | View | N/A | |
| 10/31/2011 | | $0.77 | $0.72 | | | View | N/A | |
| 8/1/2011 | | $0.77 | $0.65 | | | View | N/A | |
| 5/2/2011 | | $0.83 | $0.85 | | | View | N/A | |
| 1/31/2011 | | $0.82 | $0.89 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Haemonetics Corporation (NYSE:HAE)2017 EPS Consensus Estimate: $1.35
2018 EPS Consensus Estimate: $1.59
2019 EPS Consensus Estimate: $1.59
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.26 | $0.30 | $0.27 |
| Q2 2017 | 3 | $0.29 | $0.34 | $0.32 |
| Q3 2017 | 3 | $0.37 | $0.42 | $0.39 |
| Q4 2017 | 3 | $0.35 | $0.38 | $0.36 |
| Q1 2018 | 3 | $0.25 | $0.37 | $0.30 |
| Q2 2018 | 3 | $0.38 | $0.47 | $0.44 |
| Q3 2018 | 3 | $0.43 | $0.47 | $0.45 |
| Q4 2018 | 2 | $0.41 | $0.41 | $0.41 |
| Q1 2019 | 1 | $0.25 | $0.25 | $0.25 |
| Q2 2019 | 1 | $0.45 | $0.45 | $0.45 |
| Q3 2019 | 1 | $0.47 | $0.47 | $0.47 |
| Q4 2019 | 1 | $0.42 | $0.42 | $0.42 |
(Data provided by Zacks Investment Research)
Dividend History for Haemonetics Corporation (NYSE:HAE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Haemonetics Corporation (NYSE:HAE)Insider Ownership Percentage: 1.20%
Insider Trades by Quarter for Haemonetics Corporation (NYSE:HAE)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 5/22/2017 | Ronald Merriman | Director | Sell | 17,471 | $40.33 | $704,605.43 | |
| 12/12/2016 | Ronald G Gelbman | Director | Sell | 5,683 | $40.30 | $229,024.90 | |
| 8/17/2016 | Ronald Merriman | Director | Sell | 4,337 | $35.14 | $152,402.18 | |
| 8/4/2016 | Christopher Simon | CEO | Buy | 60,000 | $35.00 | $2,100,000.00 | |
| 10/26/2015 | Byron Selman | Insider | Sell | 344 | $32.13 | $11,052.72 | |
| 10/26/2015 | Christopher J Lindop | CFO | Sell | 436 | $32.13 | $14,008.68 | |
| 10/26/2015 | Sandra Jesse | EVP | Sell | 778 | $32.13 | $24,997.14 | |
| 10/26/2015 | Susan M Hanlon | VP | Sell | 497 | $32.13 | $15,968.61 | |
| 9/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $35.15 | $230,900.35 | |
| 9/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $35.63 | $169,776.95 | |
| 8/20/2015 | Christopher J. Lindop | CFO | Sell | 4,902 | $38.49 | $188,677.98 | |
| 8/17/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.28 | $258,030.32 | |
| 7/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $39.09 | $191,619.18 | |
| 7/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $39.59 | $260,066.71 | |
| 7/6/2015 | Peter M Allen | Insider | Sell | 30,494 | $40.19 | $1,225,553.86 | |
| 7/2/2015 | Jonathan White | Insider | Sell | 2,385 | $41.14 | $98,118.90 | |
| 6/22/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $42.51 | $208,384.02 | |
| 6/15/2015 | Brian Concannon | CEO | Sell | 6,569 | $42.51 | $279,248.19 | |
| 6/10/2015 | Susan M Hanlon | VP | Sell | 6,000 | $43.00 | $258,000.00 | |
| 6/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $41.39 | $197,223.35 | |
| 5/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.65 | $204,168.30 | |
| 5/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $40.74 | $194,126.10 | |
| 4/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $41.55 | $203,678.10 | |
| 4/1/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.51 | $212,090.15 | |
| 3/27/2015 | Susan M Hanlon | VP | Sell | 7,000 | $43.46 | $304,220.00 | |
| 3/20/2015 | Christopher J Lindop | CFO | Sell | 4,902 | $44.26 | $216,962.52 | |
| 3/10/2015 | Susan Bartlett Foote | Director | Sell | 11,328 | $43.84 | $496,619.52 | |
| 3/5/2015 | Ronald G Gelbman | Director | Sell | 7,707 | $44.76 | $344,965.32 | |
| 3/4/2015 | Ronald Merriman | Director | Sell | 14,258 | $43.80 | $624,500.40 | |
| 3/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $44.41 | $211,613.65 | |
| 2/18/2015 | Pedro P Granadillo | Director | Sell | 11,328 | $43.45 | $492,201.60 | |
| 2/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $39.15 | $186,549.75 | |
| 1/2/2015 | Brian Concannon | CEO | Sell | 4,765 | $37.20 | $177,258.00 | |
| 12/1/2014 | Brian Concannon | CEO | Sell | 4,765 | $36.72 | $174,970.80 | |
| 11/3/2014 | Brian Concannon | CEO | Sell | 4,765 | $35.86 | $170,872.90 | |
| 10/13/2014 | Peter M Allen | Insider | Sell | 36,426 | $35.22 | $1,282,923.72 | |
| 8/12/2014 | Ronald Merriman | Director | Sell | 13,602 | $35.76 | $486,407.52 | |
| 8/1/2014 | Brian Concannon | CEO | Sell | 4,380 | $35.27 | $154,482.60 | |
| 7/7/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $35.97 | $209,956.89 | |
| 6/12/2014 | Ronald G Gelbman | Director | Sell | 9,184 | $34.00 | $312,256.00 | |
| 6/6/2014 | Pedro P Granadillo | Director | Sell | 5,837 | $34.69 | $202,485.53 | |
| 5/12/2014 | Susan Bartlett Foote | Director | Sell | 9,184 | $33.16 | $304,541.44 | |
| 5/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.14 | $181,764.18 | |
| 5/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $30.01 | $138,046.00 | |
| 4/28/2014 | Peter Allen | Insider | Sell | 30,000 | $30.70 | $921,000.00 | |
| 4/7/2014 | Pedro Granadillo | Director | Sell | 5,837 | $31.98 | $186,667.26 | |
| 4/1/2014 | Brian Concannon | CEO | Sell | 4,600 | $32.71 | $150,466.00 | |
| 3/6/2014 | Ronald Gelbman | Director | Sell | 12,000 | $36.17 | $434,040.00 | |
| 3/3/2014 | Brian Concannon | CEO | Sell | 4,600 | $36.36 | $167,256.00 | |
| 2/18/2014 | Susan Hanlon | VP | Sell | 3,690 | $39.00 | $143,910.00 | |
| 2/7/2014 | Jonathan White | Insider | Sell | 1,880 | $38.66 | $72,680.80 | |
| 2/3/2014 | Brian Concannon | CEO | Sell | 7,600 | $37.63 | $285,988.00 | |
| 1/27/2014 | Susan Hanlon | VP | Sell | 3,206 | $38.37 | $123,014.22 | |
| 1/10/2014 | Susan Hanlon | VP | Sell | 4,000 | $41.80 | $167,200.00 | |
| 1/2/2014 | Brian Concannon | CEO | Sell | 7,600 | $41.58 | $316,008.00 | |
| 12/16/2013 | Susan Hanlon | VP | Sell | 4,000 | $43.50 | $174,000.00 | |
| 12/9/2013 | Susan Hanlon | VP | Sell | 3,138 | $43.07 | $135,153.66 | |
| 12/2/2013 | Brian Concannon | CEO | Sell | 7,600 | $42.31 | $321,556.00 | |
| 11/12/2013 | Michael Kelly | Insider | Sell | 61,400 | $39.70 | $2,437,580.00 | |
| 11/1/2013 | Brian Concannon | CEO | Sell | 7,600 | $39.96 | $303,696.00 | |
| 10/14/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.41 | $56,574.00 | |
| 9/13/2013 | Michael Kelly | Insider | Sell | 1,400 | $40.36 | $56,504.00 | |
| 9/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $39.87 | $518,310.00 | |
| 8/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $42.24 | $549,120.00 | |
| 7/12/2013 | Michael P Kelly | Insider | Sell | 1,400 | $44.10 | $61,740.00 | |
| 7/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.87 | $544,310.00 | |
| 6/18/2013 | Christopher J Lindop | CFO | Sell | 68,628 | $42.50 | $2,916,690.00 | |
| 6/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $42.17 | $59,038.00 | |
| 6/3/2013 | Brian Concannon | CEO | Sell | 13,000 | $41.15 | $534,950.00 | |
| 5/21/2013 | Christopher J Lindop | CFO | Sell | 42,882 | $42.00 | $1,801,044.00 | |
| 5/14/2013 | Michael P Kelly | Insider | Sell | 1,400 | $39.66 | $55,524.00 | |
| 5/1/2013 | Brian Concannon | CEO | Sell | 13,000 | $38.66 | $502,580.00 | |
| 12/3/2012 | Brian Concannon | CEO | Sell | 13,000 | $40.75 | $529,750.00 | |
| 11/12/2012 | Pedro P Granadillo | Director | Sell | 16,000 | $80.40 | $1,286,400.00 | |
| 9/4/2012 | Brian Concannon | CEO | Sell | 6,500 | $73.68 | $478,920.00 | |
| 9/4/2012 | Christopher J Lindop | CFO | Sell | 61,783 | $74.34 | $4,592,948.22 | |
(Data available from 1/1/2013 forward)
Headline Trends for Haemonetics Corporation (NYSE:HAE)
Latest Headlines for Haemonetics Corporation (NYSE:HAE)
| Source: |
|
Haemonetics Corporation (HAE) Chart for Saturday, September, 23, 2017
